Mar 06, 2020 / 04:30PM GMT
Operator
Good day, and welcome to the KOL call on masitinib in multiple sclerosis, boosted by AB Science. Today's conference is being recorded. At this time, I would like to turn the conference over to Alain Moussy. Please go ahead.
Alain Moussy - AB Science S.A. - Co-Founder, Chairman, President, CEO & Scientific Director
Welcome to our web conference led by AB Science to present masitinib results in primary progressive and non-active secondary progressive multiple sclerosis. My name is Alain Moussy. I'm the CEO of AB science, and I will have the pleasure to lead this web call with my distinguished associates and KOL and MS and also colleagues in AB Science.
We move -- let me present you the agenda. So the agenda is structured around 4 points. We'll briefly introduce the participants. We will review the landscape in multiple sclerosis and in particular, in progressive forms. And we will give, of course, the results of masitinib in the stage Phase IIb/III studies, and we'll answer your questions.
Next slide, the participants. So with me, the KOL
AB Science SA on Masitinib in Multiple Sclerosis - Conference Call Transcript
Mar 06, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers